An extracellular-matrix-specific GEF-GAP interaction regulates Rho GTPase crosstalk for 3D collagen migration Nat. Cell Biol. Sep 2014
A Heroin Addiction Severity-Associated Intronic Single Nucleotide Polymorphism Modulates Alternative Pre-mRNA Splicing of the µ Opioid Receptor Gene OPRM1 via hnRNPH Interactions J. Neurosci. Aug 2014
Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent Biochem. Biophys. Res. Commun. Aug 2014
AIRE acetylation and deacetylation: effect on protein stability and transactivation activity J. Biomed. Sci. Aug 2014
KCNA5 Other names: ATFB7; HCK1; HK2; HPCN1; KV1.5; PCN1
2 x 1 mL frozen cell vials each containing 1 x 10E6 cells
Negative by DNA staining and direct culture methods (ATTC - detailed information available upon request)
Cell Line Validation:
Gene expression: qPCR experiments determined specific over-expression of KNA5A.Figure 1.
Current-voltage relationship. Figure 2
Expression statistics. Figure 3
Pharmacology (Figure 4) - Inhibition of hKv1.5 K+ currents by known K+ channel blockers such as Psora-4, CP-339818, DPO-1, Mephetyl Tetrazole, Bupivicaine, Quinidine
Kv1.5 is a voltage-gated K+ channel which underlies the ultra-rapidly activating delayed rectifier K+ current (Ikur) found in human atrial myocytes. Kv1.5 is also expressed in the human ventricle where it is possible it contributes to the K+ current through formation of heteromultimeric K+ channels with other Kv-alpha subunits. Inhibition of Kv channels increases atrial refractory period in man â€“ this is clinically valuable for the treatment of patients suffering atrial fibrillation, but undesirable for drugs designed to have inert cardiovascular profiles.
Figure 1: In a SYBR green qPCR experiment, specific over-expression of KCN5A was determined using gene specific primers. Data are shown as fold over-expression after normalization against GAPDH.
Figure 2: Current-voltage relationship for hKv1.5 channels stably expressed in CHL cells (A). Representative recordings from CHL-Kv1.5 (B) and CHL-wild type cells (C). Experiments were conducted from a holding potential of -80mV. The depolarising step length was 200ms.
Figure 3: Expression profile: outward K+ currents of >0.6 nA were observed in 305 of 310 cells (98%), with a mean amplitude of 2.03 ± 0.85 nA (n=310; mean ± S.D.). The peak current in each cell, evoked from a depolarising pulse to +40 mV, was divided into 0.2 nA bins to create the population histogram.
Figure 4: Summary pharmacology of hKv1.5-CHL cell line. Voltage-clamp recordings were made using repeated gating steps, Vh -80mV, Vstep +40mV, 1 Hz, pulse duration 250ms. Control traces in black, test compounds in red. IC50 values were obtained by fitting concentration-response curves to values for inhibition of the 1st and 5th pulse in the train (µM, shown in table). Use-dependent and open channel block can be assessed within this protocol (note blue arrow).